- ICH M11 sets one protocol template and data standard for interventional trials of medicinal products (ICH, 2025).
- The FDA issued M11 as final guidance in May 2026, and the EU has applied it since June 11, 2026.
- M11 recommends a format: the FDA guidance carries nonbinding recommendations and no agency requires an M11 submission.
- The template puts the Schedule of Activities in Section 1.3, the first table an eCRF builder needs.
- Each M11 amendment states its primary reason and its impact on participant safety and data reliability.
Every sponsor writes protocols its own way, and the team that builds the eCRF pays for it: visits hidden in an appendix, assessments described in three places, an amendment summary that lists every comma. ICH adopted M11 on November 19, 2025, to fix the format. The FDA published it as final guidance in May 2026, and the European Medicines Agency set June 11, 2026, as its date of coming into effect. Your next protocol may arrive in this format, from a sponsor, a CRO or your own medical writer. Here is what M11 covers, what it does not require, and where it changes the study build.
What is ICH M11?
ICH M11, the Clinical electronic Structured Harmonised Protocol (CeSHarP), is a package of three documents: a guideline, a protocol template and a technical specification. The template fixes the table of contents, the section headers and the instructions for each section. The technical specification defines the data elements that let systems exchange protocol content.
The guideline gives the reason in its background section: variability in format and content among sponsors "contributes to inefficiencies" in searching, reviewing and assessing protocols. ICH released the draft for consultation in September 2022 and adopted the final version three years later. The EMA version of the technical specification runs to 302 pages, and ICH has signed an agreement with CDISC to maintain the controlled terminology behind it.
Is ICH M11 mandatory?
No. M11 recommends a format. The FDA guidance is headed "Contains Nonbinding Recommendations", and neither the FDA nor the EMA requires a protocol in M11 format to authorize a trial. What M11 offers is a structure that every regulator of the ICH regions has accepted, which removes one argument for keeping a house template.
The table sets out where M11 stands in the two regions that publish dated texts.
| Milestone | Date | Document |
|---|---|---|
| Draft released for consultation (Step 2) | September 27, 2022 | ICH M11 draft guideline and template |
| Adoption by ICH regulators (Step 4) | November 19, 2025 | Final guideline, template and technical specification |
| Final adoption by the CHMP | December 11, 2025 | EMA technical specification, Step 5 |
| FDA final guidance | May 2026 | Guidance for industry, CDER and CBER, notice in the Federal Register on May 22, 2026 |
| Coming into effect in the EU | June 11, 2026 | EMA, date stated on the Step 5 document |
Scope matters as much as dates. M11 applies to interventional clinical trials of medicinal products, across all phases and therapeutic areas, including post-approval trials. A drug-device combination developed as a drug falls inside. A clinical investigation of a medical device does not: its protocol follows ISO 14155 and the MDR, and M11 does not replace them.
What does the M11 template contain?
The template has 14 numbered sections, from the protocol summary to the references, with the information a site needs to run the trial placed at the front. ICH designed it for investigators and site staff first. Synopsis, trial schema and Schedule of Activities open the document, and reference details move to appendices that carry "equal weight and rigor".
For the team building the eCRF, five sections feed the study design. The table maps each one to what you configure in the EDC.
| M11 section | What it contains | What you build from it |
|---|---|---|
| 1.3 Schedule of Activities | Every procedure at each visit and each contact, with allowable windows | Visits, forms per visit, visit windows |
| 3 Objectives and estimands | Primary and secondary objectives, endpoints, estimands | Endpoint fields, derived variables |
| 5 Trial population | Inclusion and exclusion criteria | Eligibility form and its edit checks |
| 8 Assessments and procedures | How each assessment is performed | Items, units, ranges |
| 9 Adverse events and product complaints | Definitions, collection period, reporting | Safety forms and alert rules |
The template states that the Schedule of Activities "must capture the procedures that will be accomplished at each trial visit", including the tests used for eligibility, randomization or stratification. That one table answers most of the questions a data manager sends back to the sponsor during the study build.
What does a structured protocol change for the eCRF build?
A structured protocol puts the same information in the same place in every trial, so the study build starts from a known map instead of a search through the whole document. The gain is in location more than in automation: the technical specification defines the Schedule of Activities as one required element whose value can be a table, text or an image. It does not break visits and procedures into separate data fields, so a data manager still reads the table to configure visits.
Two situations show the difference. A CRO that builds studies for several sponsors receives protocols in as many formats; with M11, its data managers find the visit windows in Section 1.3 and the eligibility criteria in Section 5 every time, and can reuse their review checklist from one sponsor to the next. An academic sponsor-investigator who writes a first protocol gets a template with instructions in each section, and a draft that the team choosing an EDC for an academic trial can configure without guessing.
The guideline lists the reuse it has in mind: trial management, publication on clinical trial registries, and "standardised clinical trial data capture". The structure helps most with complex designs, where the Schedule of Activities changes by arm or by cohort, as in adaptive, basket and umbrella trials.
The structure does not design the eCRF for you. M11 says where the content goes, and the guideline states it does not tell a sponsor how to design a good trial. The data manager still decides how each assessment becomes a field, which steps the eCRF design follows and which edit checks protect the primary endpoint.
How does M11 handle protocol amendments?
M11 gives each amendment a fixed block at the front of the protocol, before Section 1: the primary and secondary reason, a short summary of key changes, and two yes or no questions on its likely substantial impact on participant safety or rights, and on the reliability of the data. An "Overview of Changes" table follows, and earlier amendments move to Section 12.3.
The format answers a measured problem. A Tufts CSDD study of 950 protocols, published in 2024, found that 76% of phase I to IV protocols had at least one amendment, with 3.3 amendments per protocol on average. Implementing one took 260 days from the decision to the last approval, and sites worked with different protocol versions for 215 days on average.
For the EDC team, this block tells you on the first pages whether the amendment touches the Schedule of Activities, the population or the endpoints, which decides whether the eCRF needs a new version. The hidden costs of a protocol amendment lie for the most part outside the form change, and a clear amendment summary shortens the part that sits inside it.
[[cta]]
How Datacapt works with a structured protocol
Datacapt AI drafts sections, items and fields from the protocol content you provide, with item suggestions aligned on CDISC CDASH, and writes edit checks and display conditions from the clinical logic. A data manager can ask it, in one sentence, to build the eCRF from the Schedule of Activities. With an M11 protocol, that table sits in Section 1.3, where both the agent and the data manager who reviews its suggestions expect it. The agent also drafts the UAT scripts against the configuration it has just created.
The agent works on your permissions and writes in draft, never on a live study, and each action enters the audit trail. Datacapt reports around 60% less time on the study build. The test phase stays as it is, because it is the control point. A data manager validates each suggestion before the study goes live.
Watch an agent build an eCRF from a protocol
Conclusion
ICH M11 does not oblige you to change your protocol template, and in Europe and the United States it now sits next to every other ICH guideline your trial follows. The teams that gain most are the ones who read protocols from many authors: CROs, data managers, ethics committees. If you sponsor a drug trial, ask your medical writer whether your next protocol could follow the M11 template, and send its Schedule of Activities to the team building your eCRF as the first deliverable. M11 also arrives as ICH E6(R3) Annex 2 extends good clinical practice to decentralized and pragmatic trials, two designs where a clear Schedule of Activities matters most.
[[faq]]
Sources
- International Council for Harmonisation, ICH harmonised guideline M11: Clinical electronic Structured Harmonised Protocol (CeSHarP), final version adopted on November 19, 2025, 2025
- International Council for Harmonisation, ICH M11 Clinical electronic Structured Harmonised Protocol (CeSHarP) template, Step 4, 2025
- U.S. Food and Drug Administration, M11 Clinical Electronic Structured Harmonized Protocol (CeSHarP): Guidance for Industry, 2026
- European Medicines Agency, ICH M11 Clinical electronic structured harmonised protocol (CeSHarP), Technical specification, Step 5, 2025
- Federal Register, M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability, 2026
- Tufts Center for the Study of Drug Development, New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance, Therapeutic Innovation & Regulatory Science, 2024
Is the ICH M11 protocol template mandatory?
No. The FDA guidance of May 2026 contains nonbinding recommendations, and the EMA has not made an M11 protocol a condition for authorizing a trial. Sponsors can keep their own template. M11 offers a format that all regulators of the ICH regions have accepted.
When did ICH M11 come into effect?
ICH adopted M11 at Step 4 on November 19, 2025. The FDA issued it as final guidance in May 2026, with a Federal Register notice on May 22, 2026. In the European Union, the EMA set its date of coming into effect at June 11, 2026.
Does ICH M11 apply to medical device clinical investigations?
No. M11 covers interventional clinical trials of medicinal products, including drug-device combination products developed as drugs. A clinical investigation of a medical device follows ISO 14155 and, in Europe, the MDR, which define the content of the clinical investigation plan.
What is CeSHarP?
CeSHarP stands for Clinical electronic Structured Harmonised Protocol, the full name of ICH M11. It covers a protocol template with fixed headers and instructions, and a technical specification that defines each protocol element as data for electronic exchange between sponsors, regulators and other parties.
What changes for EDC and eCRF design with ICH M11?
The information an eCRF builder needs sits in fixed places: the Schedule of Activities in Section 1.3, eligibility criteria in Section 5, assessments in Section 8. The technical specification keeps the Schedule of Activities as one table, text or image, so the data manager still reads it and decides how each assessment becomes a field.
Florentin combines clinical research know-how with a true passion for product design. Attentive to detail and obsessed with user experience, he ensures that Datacapt remains a high-performance platform that’s also intuitive and accessible to every user.
Blog & News Datacapt
News, Articles, Resources et Tutorials.
